Vanguard Group
AYTU icon

Vanguard Group’s AYTU BioPharma AYTU Stock Holding History

Vanguard Group’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$724K Hold
278,583
– – ﹤0.01% 3853
2025
Q3 		$524K Buy
278,583
+250,695
+899% +$579K ﹤0.01% 3935
2025
Q2 		$60.8K Hold
27,888
– – ﹤0.01% 4182
2025
Q1 		$33.5K Hold
27,888
– – ﹤0.01% 4219
2024
Q4 		$46.6K Hold
27,888
– – ﹤0.01% 4218
2024
Q3 		$65.5K Hold
27,888
– – ﹤0.01% 4231
2024
Q2 		$81.4K Hold
27,888
– – ﹤0.01% 4245
2024
Q1 		$84.8K Buy
27,888
+637
+2% +$1.82K ﹤0.01% 4257
2023
Q4 		$77.4K Buy
27,251
+14,278
+110% +$39.3K ﹤0.01% 4331
2023
Q3 		$35K Buy
+12,973
New +$22.7K ﹤0.01% 4450
2023
Q1 		– Sell
-48,672
Closed -$184K – 4557
2022
Q4 		$184K Buy
48,672
+37
+0.1% +$139 ﹤0.01% 4319
2022
Q3 		$180K Sell
48,635
-5,904
-11% -$44.8K ﹤0.01% 4433
2022
Q2 		$753K Buy
54,539
+18,411
+51% +$236K ﹤0.01% 4177
2022
Q1 		$780K Sell
36,128
-11,054
-23% -$275K ﹤0.01% 4285
2021
Q4 		$1.27M Sell
47,182
-1,987
-4% -$85.9K ﹤0.01% 4193
2021
Q3 		$2.83M Hold
49,169
– – ﹤0.01% 3936
2021
Q2 		$4.93M Sell
49,169
-2,927
-6% -$343K ﹤0.01% 3614
2021
Q1 		$7.92M Buy
52,096
+17,324
+50% +$2.75M ﹤0.01% 3281
2020
Q4 		$4.16M Buy
34,772
+5,928
+21% +$1.08M ﹤0.01% 3440
2020
Q3 		$6.87M Buy
28,844
+7,722
+37% +$1.98M ﹤0.01% 2990
2020
Q2 		$6M Buy
21,122
+18,265
+639% +$5.53M ﹤0.01% 3021
2020
Q1 		$857K Buy
2,857
+2,381
+500% +$460K ﹤0.01% 3538
2019
Q4 		$93K Hold
476
– – ﹤0.01% 4014
2019
Q3 		$115K Hold
476
– – ﹤0.01% 4021
2019
Q2 		$180K Hold
476
– – ﹤0.01% 3992
2019
Q1 		$159K Hold
476
– – ﹤0.01% 3956
2018
Q4 		$75K Buy
476
+338
+245% +$74.4K ﹤0.01% 4030
2018
Q3 		$76K Sell
138
-50
-27% -$46.3K ﹤0.01% 4099
2018
Q2 		$197K Buy
+188
New +$314K ﹤0.01% 3979

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group's AYTU Position: Q4 2025 in Review

Vanguard Group held its AYTU BioPharma (AYTU) position steady in Q4 2025 at 278,583 shares worth $724K. The position accounts for ﹤0.01% of the portfolio, ranked #3853.

Vanguard Group first reported a position in AYTU in Q2 2018 and has held it in 29 quarters since. The position peaked at $7.92M in Q1 2021. 39 funds tracked by Wall St. Rank hold AYTU as of Q4 2025.

  • Vanguard Group held 278,583 shares of AYTU BioPharma worth $724K as of Q4 2025.
  • Vanguard Group left its AYTU BioPharma share count unchanged in Q4 2025.
  • AYTU BioPharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3853 holding.
  • Vanguard Group first reported a position in AYTU BioPharma in Q2 2018 and has held it in 29 quarters since.
  • Vanguard Group's AYTU BioPharma position peaked at $7.92M in Q1 2021.
  • 39 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.